Far too often, we have heard about the industry's dissatisfaction with CROs, whether it be slow turnaround time, incomplete data analytics, or missed opportunities to advance drug discovery with robust biomarker analytics. "Together, we will advance precision medicine to another level while delivering personalized solutions to support clinical trials and develop next-generation diagnostics."Īcutis CEO Jibreel Sarij added, "We are reimagining biomarker discovery at the intersection of DNA, RNA, and protein diagnostics and are rewriting the rules to champion our biopharma partners. "I am honored to join Acutis Biosciences to lead the commercial team, build strong client relationships, and bring a new level of integrity and customer-focused service to the contract research market," said Mr. His extensive experience includes fostering strategic partnerships, implementing customer-focused programs, and growing complex businesses. Tremaine brings over 26 years of experience within the life sciences and CRO industry. Tremaine will oversee commercial operations with an emphasis on collaboration and relentless dedication to clients' success. Tremaine will oversee commercial operations with an emphasis on collaboration and relentless dedication to clients' success.įurthermore, the company has named Troy Tremaine as its Chief Commercial Officer. Acutis Biosciences has appointed Troy Tremaine as Chief Commercial Officer for the Biopharma Market.
0 kommentar(er)
